Pharvaris N.V. (NASDAQ: PHVS) Achieves Milestone in HAE Treatment Development
Pharvaris N.V.(US:PHVS) Financial Modeling Prep·2025-12-04 07:03Morgan Stanley maintains an "Overweight" rating for NASDAQ:PHVS, raising its price target from $37 to $41. Pharvaris' RAPIDe-3 Phase III study of Deucrictibant shows promising results for treating Hereditary Angioedema (HAE), with a median time to symptom relief of just 1.28 hours. The company plans to use the study data for marketing authorization applications, starting in the first half of 2026, as the stock value increases by 21.75%.Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on ...